ArticleFood science and biotechnology2025
Ginsenoside Rg5 inhibits the proliferation of HeLa cell through cell cycle pathway.
Article in Food science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Emerging and underexplored ginsenosides in cancer therapy (2020-2025): Beyond cytotoxic mechanisms.Journal of ginseng research · 2026Review
- Synthesis, anti-tumor evaluation, and mechanistic investigation of 3-indolylpyrazole phenoxyacetamide derivatives against chronic myeloid leukemia cells.Molecular diversity · 2026Article
- Solasodine inhibited the proliferation of gastric cancer cells through suppression of Hedgehog/Gli1 signaling.Food science and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The issue of Cervical cancer has received considerable critical attention. It was the leading cause of death in female cancer patients. Ginsenoside Rg5 has been implicated in the growth of human cancer cells, but the lack of research to determine the influence mechanism has been a significant challenge for many years. In this study, ginsenoside Rg5 was used to treat HeLa cells, and RT-qPCR, Western Blotting and RNA-seq were used to analyze the differentially expressed genes in HeLa cells to study the preliminary mechanism of ginsenoside Rg5 on cervical cancer. The results of RT-qPCR and Western Blotting were in agreement with RNA-seq analysis, which showed a down-regulation of proteins in the cell cycle pathway. These results all indicate that the expression of Minichromosome Maintenance Complex Component 6 (MCM6), Cyclin A2 (CCNA2), Cyclin-dependent kinase 6 (CDK6) and Cell division cycle 6 (CDC6) in HeLa cells treated with ginsenoside Rg5 is significantly reduced, with MCM6 exhibiting the most significant inhibitory effect, making it a potential target for the treatment of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.